Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Clinical forensic medicine in Eastern Denmark: Organisation and assessments

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  1. TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. H3K9 dimethylation safeguards cancer cells against activation of the interferon pathway

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dynamic intron retention modulates gene expression in the monocytic differentiation pathway

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Multiomic Profiling of Central Nervous System Leukemia Identifies mRNA Translation as a Therapeutic Target

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The key myeloid transcription factor (TF), CEBPA, is frequently mutated in acute myeloid leukemia (AML), but the direct molecular effects of this leukemic driver mutation remain elusive. To investigate CEBPA mutant AML, we performed microscale, in vivo chromatin immunoprecipitation sequencing and identified a set of aberrantly activated enhancers, exclusively occupied by the leukemia-associated CEBPA-p30 isoform. Comparing gene expression changes in human CEBPA mutant AML and the corresponding CebpaLp30 mouse model, we identified Nt5e, encoding CD73, as a cross-species AML gene with an upstream leukemic enhancer physically and functionally linked to the gene. Increased expression of CD73, mediated by the CEBPA-p30 isoform, sustained leukemic growth via the CD73/A2AR axis. Notably, targeting of this pathway enhanced survival of AML-transplanted mice. Our data thus indicate a first-in-class link between a cancer driver mutation in a TF and a druggable, direct transcriptional target.

OriginalsprogEngelsk
TidsskriftScientific American
Vol/bind5
Udgave nummer7
Sider (fra-til)eaaw4304
ISSN0036-8733
DOI
StatusUdgivet - 1 jan. 2019

ID: 57758371